CH-1 for AUD.

Digital CBT modules for Alcohol Use Disorder.

Pending FDA approval, CH-1 for AUD provides self-directed, web-based digital CBT lessons to enhance cognitive behavior skills in adult patients with AUD.

Pursuing FDA Approval

CHESS Health is currently pursuing FDA approval for CH-1 for AUD, a web-based, prescription digital therapeutic intended to deliver cognitive behavioral therapy (CBT) to adult patients with AUD to increase abstinence from alcohol.  
 
CH-1 for AUD is intended to provide CBT as an adjunct to behavioral health treatment and/or pharmacotherapy for patients 22 years of age and older who are currently enrolled in outpatient treatment under the supervision of a clinician.

CH-1 for AUD has demonstrated efficacy in multiple clinical trials in adult patients with AUD.

This product is currently not available for license or purchase.

Proven Impact

Peer-Reviewed Findings
CH-1 for AUD has been tested in multiple clinical trials. The peer-reviewed findings of its most recent study can be found.

Want to
learn more?

Get in touch to see how we can help.